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Abstract Syntaxin 1C is an alternative splice variant of HPC-
1/syntaxin 1A; the latter participates in neurotransmitter re-
lease and is assigned to the gene domain responsible for Wil-
liams’ syndrome (WS). It is expressed in the soluble fraction
extracted from human astroglioma cell lines T98G and
U87MG. Quantitative immunoblot and indirect immuno£uores-
cence analyses revealed that the expression of syntaxin 1C was
upregulated by phorbol 12-myristate 13-acetate (PMA), but not
by forskolin. A protein kinase C (PKC) inhibitor suppressed this
enhancement. These results suggest that syntaxin 1C expression
is regulated via the PKC signal pathway. This is the ¢rst report
of a signal transduction system that directly a¡ects the expres-
sion of syntaxin protein.
6 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
Key words: Syntaxin 1; Astroglioma; Phorbol-ester;
Protein kinase C; Protein kinase C inhibitor
1. Introduction
According to the soluble N-ethylmaleimide-sensitive fusion
protein (NSF) attachment protein receptor (SNARE) hypoth-
esis explaining the mechanism of intracellular transport, syn-
taxins function in intracellular membrane fusion events [1^4].
18 mammalian syntaxins have been identi¢ed, most of which
are associated with speci¢c intracellular membrane compart-
ments by virtue of their carboxyl-terminal hydrophobic trans-
membrane domain (TMD) [5,6]. Recently, several syntaxin
isoforms lacking a TMD have been reported. Syntaxin 11
behaves like membrane protein, probably via lipid anchoring,
despite the lack of an obvious traditional TMD [7,8]. Syntax-
ins 2D, 3D and 16C, which are generated by alternative splic-
ing, are isoforms without a TMD [9^11]. However, the func-
tions of syntaxins lacking a TMD have not been elucidated.
Syntaxin 1C, which lacks the hydrophobic carboxyl-termi-
nal containing the TMD characteristic of the syntaxin family,
is generated by alternative splicing of syntaxin 1A (HPC-1)
[12]. The latter participates in neurotransmitter release [1,6].
The syntaxin 1A and 1C genes exist in the gene domain that
causes the congenital neurodevelopmental disorder Williams’
syndrome (WS) when deleted [13,14].
Recently, it was suggested that expression of syntaxin 1A
and 1B mRNA was regulated in neuronal cells [15,16]. How-
ever, it is not known whether the expression of syntaxin pro-
tein isoforms lacking a TMD is also regulated.
This paper reports that syntaxin 1C is expressed in astro-
glial cells as a soluble protein. Furthermore, immunoblotting
and indirect immuno£uorescence analyses revealed that syn-
taxin 1C protein expression was enhanced by phorbol-ester
stimulation, but not by forskolin or a non-e¡ectable analog
of phorbol-ester, and that protein kinase C (PKC) inhibitor
treatment blocked the enhanced expression of syntaxin 1C
protein caused by phorbol-ester.
2. Materials and methods
2.1. Reverse transcriptase-polymerase chain reaction (RT-PCR) and
DNA cloning
Total cellular RNA was extracted using a QIA-Amp RNA extrac-
tion kit (Qiagen). RT-PCR analysis was carried out using an RNA
PCR kit (TAKARA) according to the manufacturer’s instructions.
The primers used to distinguish human syntaxins 1A and 1C in the
RT-PCR analysis were 5P-CTTTGCCTCTGGGATCATCATGG-3P
(syntaxin 1 sense) and 5P-CCTTGCTCTGGTACTTGACGGCC-3P
(syntaxin 1 antisense). For semi-quantitative PCR analysis [17], the
primer for L-actin as an internal control was purchased from Maxim
Biotech, Inc. The PCR cycling pro¢le for syntaxin consisted of a
5-min initial denaturing at 95‡C, followed by 40 cycles of 95.5‡C
for 1 min, 55‡C for 0.5 min, and 72‡C for 0.5 min using a Perkin-
Elmer 9700 thermal cycler. The ampli¢cation products were stained
with ethidium bromide. To clone human syntaxins, the following
oligonucleotide primers were designed: 5P-TTAGATCTATGAAG-
GACCGAACCCAGGAG-3P (syntaxins 1A and 1C sense), 5P-AA-
GAATTCTAGGCGAAGATGCCCCCAAC-3P (syntaxin 1A anti-
sense), and 5P-AAGAATTCTCAATCATCTCTCCCTGCGG-3P (syn-
taxin 1C antisense). These primers were used in RT-PCR with mRNA
isolated from a human brain library (BIO101) and T98G human
astroglioma cells (see Fig. 1B). The full-length human syntaxin
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cDNAs were inserted into the BamHI and EcoRI sites of pcDNA3
vector (Invitrogen). In addition, human syntaxins 1A and 1C used as
controls for immunoblotting were ampli¢ed using the following prim-
ers: 5P-TTAGATCTATGAAGGACCGAACCCAGGAG-3P (syntax-
ins 1A and 1C sense), 5P-AACTCGAGTAGGCGAAGATGCCCCC-
AAC-3P (syntaxin 1A antisense) and 5P-AACTCGAGTCAATCA-
TCTCTCCCTGCGG-3P (syntaxin 1C antisense). Syntaxins 1A and
1C were subcloned into the BamHI and XhoI sites of pPROEX-1
vector (Life Technologies). The sequences of the subcloned syntaxins
were con¢rmed using an ABI 377 sequencer (ABI). The recombinant
proteins were puri¢ed as reported [18].
2.2. Preparation of anti-syntaxin 1C antiserum
To prepare antiserum against syntaxin 1C, a peptide (pep-1C :
CPEPQPNPEEGALWSSGAPGPAGRDD) unique to human syntax-
in 1C was synthesized with a peptide synthesizer. This peptide was
puri¢ed by high performance liquid chromatography and con¢rmed
by mass spectroscopic analysis. Antiserum against pep-1C peptide was
raised in rabbit and IgG was puri¢ed as described [19].
2.3. Cell culture and drug treatment
T98G, NB-1, IMR-32, and PC12h cell lines were purchased from
HSRRB (Japan). Human astroglioma cell lines (U87MG, U138,
U343MGa, and SF126) were kindly provided by Dr. Hiroki Sawa
(Kyorin University, Japan). Cells were maintained in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal
calf serum (FCS) (Sigma), penicillin (100 Wg/ml), and streptomycin
(100 Wg/ml).
For drug stimulation, the cells were treated for 3^48 h with 1^10
WM phorbol 12-myristate 13-acetate (PMA) (Sigma), 10 WM 4K-PMA
(Sigma), or 10 WM forskolin (RBI). For the PKC blocking experi-
ment, cells were pretreated for 2 h with 5 WM GF109203X (GF), a
bisindolylmaleimide, as a general PKC inhibitor (Calbiochem), and
then incubated for 12 h both with PMA and GF.
2.4. Isolation of transformants overexpressing syntaxin
T98G and U87MG cells grown on 90-mm plastic dishes were tryp-
sinized after washing with phosphate-bu¡ered saline (PBS) twice, and
resuspended into 0.3 ml of serum-free DMEM on ice. Using a Bio-
Rad gene pulsar, 1U106 cells were electro-transfected with 150 Wg/ml
of pcDNA3 syntaxins. The electroporation was carried out at a ¢eld
strength of 0.75 kV/cm and a capacitance of 960 WF. In order to
obtain transformants, the cells were cultured in DMEM containing
neomycin (800 Wg/ml) for 2 weeks. Ultimately, three syntaxin trans-
formant cell lines were isolated.
2.5. Subcellular fractionation
Cells grown in 75-cm2 dishes were fractionated as described previ-
ously with slight modi¢cation [20]. The cells were scraped out with a
rubber policeman into 0.5 ml of ice-cold homogenization bu¡er (250
mM sucrose, PBS, 1 mM ethylenediamine tetraacetic acid (EDTA),
1 mM ethyleneglycol-bis-(L-aminoethylether)-N,N,NP,NP-tetraacetic
acid (EGTA), 0.1 mM phenylmethylsulfonyl £uoride (PMSF), 10
Wg/ml pepstatin, 10 Wg/ml aprotinin, 3 Wg/ml leupeptin, pH 7.4) and
homogenized with 30 strokes on ice in a micro-tissue grinder (Spec-
trum). The homogenate was centrifuged at 1000Ug for 5 min at 4‡C
to eliminate the nuclei and large cellular debris, and the resulting
supernatant was centrifuged at 8000Ug for 10 min at 4‡C. The sub-
sequent supernatant was centrifuged at 100 000Ug for 60 min at 4‡C.
The pellet was washed in homogenization bu¡er, and centrifuged
again at 100 000Ug for 60 min at 4‡C. The resulting pellet was re-
suspended in PBS bu¡er (pH 7.4) containing 6 M urea, 0.5% Triton
X-100, 0.5% NP-40, 0.1% sodium dodecyl sulfate (SDS), 0.1 mM
EDTA and 1 mM EGTA, and was centrifuged at 10 000Ug for 30
min at 4‡C. The resulting supernatant was collected as a crude mem-
brane extract.
2.6. A⁄nity column puri¢cation of syntaxin 1C
Syntaxin 1C was puri¢ed from cells in an a⁄nity column conju-
gated with anti-syntaxin 1A monoclonal antibody (14D8). The a⁄nity
column was made by coupling 10 mg of the puri¢ed anti-syntaxin 1A
IgG (14D8) to HiTrap-NHS-activated Sepharose 4FF (Pharmacia).
Cytosol was prepared by freezing and thawing 4U107 cells in HEPES
bu¡er (10 mM Naþ^HEPES, 135 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 0.1 mM PMSF, 10 Wg/ml pepstatin, 10 Wg/ml aprotinin, 3 Wg/
ml leupeptin, pH 7.4) and then centrifuging the preparation at
100 000Ug ; this was then loaded onto the column and washed with
15 column volumes of HEPES. Syntaxin 1C was eluted from the
column with 0.1 M glycine^HCl (pH 3.0), and then each fraction
was neutralized using 1 M Tris (pH 9.5). The peak protein fraction
was immunoblotted as the eluant.
2.7. Immunoblotting and quantitative analysis
Cells on 35-mm dishes (Falcon) were treated with 10% trichloric
acid (TCA) on ice for 30 min. The cells were scraped out and centri-
fuged at 15 000 rpm and 4‡C, for 30 min. The precipitate was solu-
bilized with 70 Wl of 8 M urea/1% SDS/10 mM Tris^Cl (pH 7.5). After
sonication on ice, the samples were centrifuged at 15 000 rpm and
4‡C, for 30 min, and the supernatant was obtained. The protein con-
centration was measured with a DC-protein assay (Bio-Rad).
The samples were separated by 12% SDS^polyacrylamide gel elec-
trophoresis (PAGE), and the blotted PVDF membranes were treated
with blocking bu¡er (5% (w/v) skim milk, 1% (w/v) bovine serum
albumin (BSA), PBS) and exposed to anti-syntaxin 1A monoclonal
IgG (14D8) (0.1 Wg/ml) [21], anti-syntaxin 1C IgG (1 Wg/ml), anti-
syntaxin 2 polyclonal antibody (0.2 Wg/ml) (Stressgen Biotech.),
anti-syntaxin 3 polyclonal antibody (1 Wg/ml) (Sigma) or anti-syntaxin
4 monoclonal IgG (0.1 Wg/ml) (Transduction Lab.). The membranes
were exposed to horseradish peroxidase-conjugated anti-mouse IgG
coupled to horseradish peroxidase (diluted 1:10 000) (ICN) or anti-
rabbit IgG coupled to horseradish peroxidase (diluted 1:5000) (Cap-
pel). Then, the membranes were enhanced with chemiluminescence
reagent (Amersham-Pharmacia).
For the peptide suppression experiment, anti-syntaxin 1C antibody
was preincubated with 100 Wl of 2 mg/ml pep-1C peptide at 37‡C for
3 h and the preincubated antibody was used in immunoblotting.
For quantitative analysis of syntaxin 1C, after drug stimulation,
15-Wg protein samples were loaded and the syntaxin 1C signal was
obtained by immunoblotting with anti-syntaxin 1C IgG and 14D8.
Then, the membranes used for syntaxin 1C Western blotting were
stripped with 0.1 M glycine^HCl (pH 3.0), neutralized, and then
treated with anti-K-tubulin IgG (DM1A) (diluted 1:5000) (Sigma) as
an internal control. Expression of syntaxins 2, 3 and 4 was also
quantitated by the same procedures except using anti-syntaxin 2,
3 and 4 antibody, respectively. The intensities of the immunoblotted
signals were measured using NIH Image and the intensity of the
syntaxin 1C signal was normalized with that of tubulin.
2.8. Indirect immuno£uorescence studies
The cells were cultured on Lab-Tek II 8-well chamber slides (Nunc).
Immunostaining was carried out as described previously with slight
modi¢cation [22]. Brie£y, after removing the medium, the dishes were
washed twice in PBS. The cells were ¢xed and permeabilized for 15
min with 4% paraformaldehyde (PFA) containing 0.1% Triton X-100
and PBS. After treatment with blocking solution (5% goat serum,
PBS), the cells were incubated with anti-syntaxin 1A IgG (14D8)
(1 Wg/ml) or anti-syntaxin 1C IgG (10 Wg/ml) in PBS containing 5%
goat serum and 1% BSA. After washing with PBS, cells were exposed
to anti-mouse IgG or anti-rabbit IgG coupled to Alexa 488 (diluted
1:1000) (Molecular Probes). Stained cells were examined using a con-
focal laser scanning electron microscope (Zeiss LSM 410).
To measure the proportion of cells strongly expressing syntaxin 1C,
confocal images were processed using NIH Image. A strongly express-
ing cell was de¢ned as one exceeding the threshold staining strength of
control cells. At least 300 cells were examined in triplicate.
2.9. Statistical analysis
The results are presented as the meansUS.E.M. of triplicate sam-
ples from at least two independent experiments. The data were ana-
lyzed using one-way analysis of variance. P values less than or equal
to 0.05 were considered signi¢cant.
3. Results and discussion
3.1. PCR analysis of alternatively spliced variants of syntaxin 1
Syntaxin 1A is localized to the plasma membrane of axons
and presynaptic terminals in neuronal cells and is involved in
the exocytosis of neurotransmitters in neuronal cells [23].
Although syntaxin 1C mRNA is expressed in human fat, skel-
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etal muscle, liver, and brain [12], its intracellular expression as
a protein has not yet been localized. It is well known that
neurons express syntaxin 1A. However, it is not known which
cell types express syntaxin 1C in the brain.
First, we carried out an RT-PCR analysis using several cell
lines derived from human brain. Human neuroblastoma (NB-1
and IMR-32) and astroglioma (T98G, U87MG, U138,
U343MGa and SF126) cell lines were used. Human syntaxins
1A and 1C share all but 91 nucleotides of a syntaxin 1C-
speci¢c region generated by alternative splicing (see Fig.
1A). Therefore, the PCR analysis was carried out using a
pair of PCR primers that distinguished syntaxin 1A and 1C
mRNA by molecular weight and could detect genomic con-
tamination during mRNA preparation (Fig. 1A). A genomic
DNA clone (BAC 27H2) containing the human syntaxin 1A
and 1C genes [24] was used as a control.
We found that all of the astroglioma cell lines studied ex-
pressed syntaxin 1C, but not syntaxin 1A, whereas the two
human neuroblastoma cell lines expressed only syntaxin 1A.
Fig. 1B shows representative results of RT-PCR from human
neuroblastoma NB-1 and astroglioma T98G. The 480-bp
product expected for syntaxin 1C mRNA was detected only
in astroglioma T98G, and not in neuroblastoma NB-1 (Fig.
1B). By contrast, the 390-bp product expected for syntaxin 1A
Fig. 1. PCR analysis of alternatively spliced variants of syntaxin 1.
A: Schematic representation of the syntaxin 1A variants generated
by alternative splicing: coding region (open boxes), syntaxin 1C
unique sequence (dark boxes), and 3P-untranslated region (bar). The
arrowheads indicate the positions of primer sets a and b. With
primer set b, the syntaxin 1A and 1C genes can be discriminated by
their sizes (see B). B: PCR identi¢cation of alternatively spliced var-
iants of syntaxin 1 in several cell lines. PCR was performed with
the two primer sets described in A. A genome containing syntaxin
1A (BAC 27H2) as a negative control, ¢rst strand cDNA from
T98G astroglioma, ¢rst strand cDNA from NB-1 neuroblastoma,
and a ¢rst strand cDNA library from human brain tissue were ana-
lyzed on 1% agarose gels.
Fig. 2. Identi¢cation of syntaxin 1C protein in cells by immunoblot-
ting. A: Syntaxin 1C was expressed in human astroglioma cell line
T98G. Syntaxin 1C from T98G parent cells was compared with that
from T98G cells expressing exogenous syntaxin 1C. Total homoge-
nates of cells treated with 10% TCA were immunoblotted. Immuno-
blotting was carried out using anti-HPC-1/syntaxin 1A antibody
(14D8), anti-syntaxin 1C antibody (K-syn 1C), or anti-syntaxin 1C
antibody in the presence of peptide of the syntaxin 1C-speci¢c re-
gion (+pep). The arrowhead indicates HPC-1/syntaxin 1A (Mr
35 000 Da band). A syntaxin 1C signal was detected in the total ly-
sate of T98G cells. B: Immunoblotting of the subcellular fractions
in T98G transformants. The soluble and membrane fractions of
T98G cells expressing syntaxin 1A or syntaxin 1C were immuno-
blotted using (left panel) anti-HPC-1/syntaxin 1A antibody (14D8),
(middle panel) anti-syntaxin 1C antibody (K-syn 1C), or (right pan-
el) anti-syntaxin 1C antibody in the presence of the peptide of the
syntaxin 1C-speci¢c region (+pep 1C). Syntaxin 1C was present in
the soluble fraction. C: Immunoblotting of a⁄nity-puri¢ed syntaxin
1C in T98G parent cells. The soluble fraction of T98G cells (4U107
cells) was a⁄nity-puri¢ed using an anti-syntaxin 1A (14D8) anti-
body-conjugated column and the £ow through (FT), eluant (EL),
and starting mixture (ST) were immunoblotted. The arrowhead indi-
cates syntaxin 1C. The syntaxin 1C signal was revealed by conden-
sation with a⁄nity puri¢cation. This syntaxin 1C signal was blocked
by the addition of pep 1C.
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was detected only in neuroblastoma NB-1 (Fig. 1B). In the
human brain library, both the syntaxin 1A and 1C gene prod-
ucts were detected (Fig. 1B). Therefore, our next experiments
sought to detect syntaxin 1C protein in astroglioma cells.
3.2. Identi¢cation of syntaxin 1C protein in T98G cells by
immunoblotting
In order to determine the speci¢city of syntaxin 1C anti-
body, we carried out an immunoblot analysis of recombinant
syntaxins 1A and 1C expressed by Escherichia coli. An anti-
body for the N-terminal region of syntaxin 1A (14D8) recog-
nized both syntaxins 1A and 1C, whereas an antibody raised
against the C-terminal unique region of syntaxin 1C speci¢-
cally recognized syntaxin 1C (data not shown).
We next investigated the expression of syntaxin 1C protein
in astroglioma cells. T98G transformants expressing syntaxin
1A or 1C were used as controls. Fig. 2A shows that syntaxin
1C protein is present in T98G astroglioma cells. The signal of
the anti-syntaxin 1C antibody was suppressed by preincuba-
tion with syntaxin 1C-speci¢c peptide (pep-1C) (Fig. 2A). In-
terestingly, the apparent molecular weight of syntaxin 1C on
SDS^PAGE was almost the same as that of syntaxin 1A,
although the theoretical molecular weights of syntaxins 1A
and 1C di¡er (Fig. 2A). This result con¢rmed the report of
Jagadish et al. [12]. However, the amount of syntaxin 1C
protein expressed in T98G cells appeared much lower than
that of syntaxin 1A protein in PC12h, which strongly ex-
presses syntaxin 1A protein (data not shown).
3.3. Intracellular localization of syntaxin 1C in T98G
transformants
In order to localize syntaxin 1C within astroglioma cells, we
subfractionated T98G or U87MG transformants of syntaxin
1C to obtain soluble and crude membrane fractions. Exoge-
nous syntaxin 1C protein was detected in the soluble fraction
by Western blotting, whereas syntaxin 1A protein was de-
tected only in the crude membrane fraction (Fig. 2B).
We tried to detect syntaxin 1C in T98G parent cells after
condensation using a⁄nity column chromatography, since the
amount of native syntaxin 1C expressed is too small to ana-
lyze. The soluble fraction of T98G (4U107 cells) was puri¢ed
in an a⁄nity column coupled with anti-syntaxin 1A monoclo-
nal antibody (14D8), and immunoblotted. As shown in Fig.
2C, a syntaxin 1C signal was detected in parent cells using
both 14D8 and syntaxin 1C antibody, but not when anti-syn-
taxin 1C antibody was preincubated with syntaxin 1C-speci¢c
peptide (pep-1C) (Fig. 2C). A similar result was observed in
U87MG cells (data not shown). These results show that syn-
taxin 1C protein was present in the soluble fraction, but not in
the membrane fraction, unlike syntaxin 1A protein.
Syntaxin 1C possesses the same N-terminal domain (1^225
amino acid residues) as syntaxin 1A, however, loses TMD and
the latter half of H3 domain which were converted into the
novel C-terminal proline-rich region of 35 residues generated
by alternative splicing. Since the H3 domain (191^267 residues
in syntaxin 1A) is necessary for interaction with most of
SNAREs [25^28], the C-terminal of syntaxin 1C would lose
capacity for binding with SNAREs except n-Sec/Munc18 and
SNAP-25. In addition, we found that syntaxin 1C is detected
only in soluble fraction (Fig. 2B, C), suggesting that syntaxin
1C did not interact with, at least, other membrane-bound
SNAREs in astroglioma cells.
3.4. Phorbol-ester stimulation induced expression of syntaxin
1C protein
In order to determine whether the expression of syntaxin
1C is regulated via any signal transduction system, T98G cells
were stimulated with forskolin and PMA, which activate pro-
tein kinase A (PKA) and PKC, respectively.
As shown in Fig. 3A, RT-PCR analysis con¢rmed that
stimulation of T98G cells with 10 WM PMA appeared to in-
crease the expression of syntaxin 1C mRNA (480 bp signal).
However, syntaxin 1A signal (390 bp) was not observed in the
Fig. 3. Expression of syntaxin 1C in T98G astroglioma cells treated
with PMA and forskolin. A: RT-PCR analysis of syntaxin 1C ex-
pression in T98G cells treated for 12 h with 10 WM PMA. RT-PCR
was performed as shown in Fig. 1. The syntaxin 1C PCR product
(480 bp), but not that of syntaxin 1A (390 bp), appeared to increase
(3.09U 0.55-fold) in T98G cells with PMA stimulation. However,
the syntaxin 1A was not detected in control nor PMA-stimulated
cells. A ¢rst strand cDNA library from human brain tissue (brain)
was also analyzed to distinguish syntaxins 1A and 1C. B: PMA
dose dependence of syntaxin 1C expression. T98G cells were treated
for 12 h with 0^10 WM PMA. 15 Wg of TCA lysates were immuno-
blotted with 14D8 (35 kDa). The membranes were then immuno-
blotted with anti-K-tubulin IgG (55 kDa). C: Expression of syntaxin
1C in T98G cells treated for 12 h with 10 WM forskolin, 4K-PMA,
PMA, or PMA plus 5 WM PKC inhibitor, GF. D: Quanti¢cation of
the syntaxin 1C signal in cells treated with drugs. Quantitative den-
sitometric analysis was performed using NIH Image. The values are
expressed in arbitrary units of syntaxin 1C density relative to tubu-
lin density. The results are the meansUS.E.M. of nine independent
experiments. The syntaxin 1C expression increased in T98G cells
with PMA stimulation. The results were compared to those for
0 WM PMA (0.1% dimethylsulfoxide (DMSO)) statistically. 0 WM
PMA=1.07U 0.18, 4K-PMA=1.09U0.25 (Ps 0.05), 1 WM PMA=
2.65U 0.52 (*P6 0.01), 10 WM PMA=4.91U 0.56 (**P6 0.001), for-
skolin= 0.84U 0.16 (Ps 0.05), PMA+GF=1.29U 0.17 (Ps 0.05).
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control nor PMA-stimulated cells by PCR (Fig. 3A). Further-
more, quantitative immunoblot analysis demonstrated that
syntaxin 1C protein expression was enhanced about two-
fold with 1 WM PMA and about ¢ve-fold with 10 WM PMA
stimulation (Fig. 3B, C, D), whereas the amount of plasma
membrane syntaxins (syntaxins 2, 3 and 4) was not changed
by PMA stimulation (data not shown). This e¡ect of PMA at
high concentration suggests that a low-responsive isoform of
conventional or novel PKC activated by PMA participates in
the induction of syntaxin 1C in T98G cells [29]. By contrast,
in the presence of 10 WM forskolin, syntaxin 1C expression
did not change signi¢cantly (0.84U 0.16) (Fig. 3C, D). 10 WM
4K-PMA, a non-e¡ective analog of PMA, had no e¡ect
(1.09U 0.25) (Fig. 3C, D).
We also carried out indirect immuno£uorescence analysis to
study the e¡ect of PMA. In control cells, intracellular expres-
sion of syntaxin 1C was generally weak, although a few cells
showed high expression (Fig. 4A). We found that PMA en-
hanced the expression of syntaxin 1C in most cells and the
number of cells strongly expressing it increased with PMA
stimulation (Fig. 4A, B). This phenomenon was not observed
in PC12h cells expressing syntaxin 1A and not syntaxin 1C
(data not shown). By contrast, forskolin and 4K-PMA were
not e¡ective (Fig. 4A, B). At present, the reason for the di¡er-
ent responses by T98G cells is not clear.
Furthermore, immunoblot analysis showed that upregula-
tion of syntaxin 1C expression increased for at least 24 h
during PMA stimulation (data not shown) and indirect im-
Fig. 4. PMA stimulation of the intracellular expression of syntaxin 1C is dependent on stimulation time. A: Intracellular expression of syntaxin
1C in T98G cells treated with PMA and forskolin. Indirect immuno£uorescence analysis of T98G astroglioma cells treated with 10 WM forsko-
lin, 10 WM PMA or 10 WM 4K-PMA for 24 h. B: Proportion of cells strongly expressing syntaxin 1C with drug treatment. The results are giv-
en as percentages (meansUS.E.M.), n=3. The number of cells strongly expressing syntaxin 1C with PMA treatment exceeded that for control
cells or with forskolin or 4K-PMA at 3 h (*P6 0.05), 12, 24, or 48 h (**P6 0.01). C: PKC inhibitor suppresses enhancement of syntaxin 1C
expression by PMA. T98G astroglioma cells were treated with 1 WM PMA for 12 h (PMA). In order to know the e¡ect of PKC inhibitor, the
cells were pretreated with 5 WM GF for 3 h and further incubated with 5 WM GF alone (GF) or with both 1 WM PMA and 5 WM GF
(PMA+GF) for 12 h.
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muno£uorescence analysis showed that the number of cells
strongly expressing syntaxin 1C increased during PMA stim-
ulation (Fig. 4B). This slow, sustained activation of syntaxin
1C by PMA suggests an indirect process, requiring de novo,
ongoing protein synthesis or suppressing protein degradation.
To ensure that the increase in syntaxin 1C expression with
PMA was a speci¢c e¡ect, we treated the cells with 5 WM GF,
a bisindolylmaleimide, which inhibits the activity of all three
PKC isoforms (conventional, novel, atypical) by competing
for the ATP binding site [30,31]. Figs. 3C, 3D, and 4C
show that syntaxin 1C expression was no longer enhanced
by treatment with this PKC inhibitor. These results imply
that syntaxin 1C expression is regulated via the PKC signaling
pathway. Since it has been reported that the expression of
syntaxin 1A mRNA is upregulated by forskolin, but not by
PMA [15], perhaps syntaxin 1A and 1C expressions are regu-
lated in di¡erent manners in neuronal and glial cells, respec-
tively. From the viewpoint of the regulation of gene transcrip-
tion, respective assay systems using neuroblastoma and
astroglioma cells expressing syntaxins 1A and 1C will be use-
ful for studying the mechanisms regulating syntaxin 1 expres-
sion. Since it was known that the syntaxin family participates
in the intracellular membrane transport mechanism, it is pos-
sible that syntaxin 1C participates in intracellular transport.
However, at present, the physiological function and expres-
sion mechanism of syntaxin 1C are unknown, and further
studies are clearly necessary.
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